The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J01 | Antibacterials for systemic use | |
| 3 | J01D | Other beta-lactam antibacterials | |
| 4 | J01DH | Carbapenems | |
| 5 | J01DH56 |
| Active Ingredient | Description | |
|---|---|---|
| Imipenem, Cilastatin and Relebactam |
The bactericidal activity of imipenem results from the inhibition of penicillin binding proteins (PBPs) leading to inhibition of peptidoglycan cell wall synthesis. Cilastatin limits the renal metabolism of imipenem and does not have antibacterial activity. Relebactam is a non-beta lactam inhibitor of Ambler class A and class C beta-lactamases, including class A Klebsiella pneumoniae carbapenemase (KPC) and extended-spectrum beta-lactamases (ESBLs), and class C (AmpC-type) beta-lactamases including Pseudomonas-Derived Cephalosporinase (PDC). Relebactam does not inhibit class B enzymes (metallo-beta-lactamases) or class D carbapenemases. Relebactam has no antibacterial activity. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| RECARBRIO Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RECARBRIO Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
